Osterweis Capital Management Inc Summit Therapeutics Inc. Transaction History
Osterweis Capital Management Inc
- $2.15 Billion
- Q4 2024
A detailed history of Osterweis Capital Management Inc transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Osterweis Capital Management Inc holds 5,000 shares of SMMT stock, worth $98,500. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,000
Previous 5,000
-0.0%
Holding current value
$98,500
Previous $109,000
18.35%
% of portfolio
0.0%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
233Shares Held
84.5MCall Options Held
1.97MPut Options Held
2.86M-
Baker Bros. Advisors LP New York, NY24.4MShares$481 Million4.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$230 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$156 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$129 Million0.01% of portfolio
-
State Street Corp Boston, MA5.6MShares$110 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.96B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...